Clinical Impact of Immune Checkpoint Inhibitors and Chemotherapy in the First-Line Treatment of Metastatic Urothelial Carcinoma with Variant Histology.
- DOI
- 10.1159/000552945
- Published
- 2026 Jun 9
- Container
- Urologia internationalis
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1159/000552945,
title = {Clinical Impact of Immune Checkpoint Inhibitors and Chemotherapy in the First-Line Treatment of Metastatic Urothelial Carcinoma with Variant Histology.},
author = {Isgandarov A and Al-Nader M and Yesilyurt UU and Katayeu Y and Mahmoud O and Kesch C and Hadaschik B and Grünwald V and Darr C},
year = {2026},
journal = {Urologia internationalis},
doi = {10.1159/000552945},
url = {https://doi.org/10.1159/000552945}
}RIS
TY - JOUR TI - Clinical Impact of Immune Checkpoint Inhibitors and Chemotherapy in the First-Line Treatment of Metastatic Urothelial Carcinoma with Variant Histology. AU - Isgandarov A AU - Al-Nader M AU - Yesilyurt UU AU - Katayeu Y AU - Mahmoud O AU - Kesch C AU - Hadaschik B AU - Grünwald V AU - Darr C PY - 2026 JO - Urologia internationalis DO - 10.1159/000552945 UR - https://doi.org/10.1159/000552945 ER -
APA
A, I., M, A., UU, Y., Y, K., O, M., C, K., B, H., V, G., & C, D. (2026). Clinical Impact of Immune Checkpoint Inhibitors and Chemotherapy in the First-Line Treatment of Metastatic Urothelial Carcinoma with Variant Histology.. Urologia internationalis. https://doi.org/10.1159/000552945
Source records
- pubmed · retrieved 2026-09-26T00:05:21.442Z